Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.65 CAD -0.77% Market Closed
Market Cap: 135.1m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Wall Street
Price Targets

RX Price Targets Summary
Biosyent Inc

Wall Street analysts forecast RX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RX is 11.99 CAD with a low forecast of 11.87 CAD and a high forecast of 12.34 CAD.

Lowest
Price Target
11.87 CAD
2% Upside
Average
Price Target
11.99 CAD
3% Upside
Highest
Price Target
12.34 CAD
6% Upside
Biosyent Inc Competitors:
Price Targets
SDZ
Sandoz Group AG
13% Upside
293480
Hana Pharm Co Ltd
65% Upside
4886
ASKA Pharmaceutical Holdings Co Ltd
21% Upside
4503
Astellas Pharma Inc
31% Upside
FAE
Faes Farma SA
17% Upside
CLN
Celon Pharma SA
10% Downside
MEDCL
Medincell SA
34% Upside
688356
Jenkem Technology Co Ltd
75% Upside

Revenue
Forecast

Revenue Estimate
Biosyent Inc

For the last 8 years the compound annual growth rate for Biosyent Inc's revenue is 9%. The projected CAGR for the next 3 years is 11%.

9%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Biosyent Inc

For the last 8 years the compound annual growth rate for Biosyent Inc's operating income is 5%. The projected CAGR for the next 4 years is -7%.

5%
Past Growth
-7%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Biosyent Inc

For the last 8 years the compound annual growth rate for Biosyent Inc's net income is 7%. The projected CAGR for the next 3 years is 5%.

7%
Past Growth
5%
Estimated Growth
Estimates Accuracy
26%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RX's stock price target?
Price Target
11.99 CAD

According to Wall Street analysts, the average 1-year price target for RX is 11.99 CAD with a low forecast of 11.87 CAD and a high forecast of 12.34 CAD.

What is Biosyent Inc's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Biosyent Inc's revenue is 9%. The projected CAGR for the next 3 years is 11%.

What is Biosyent Inc's Operating Income forecast?
Projected CAGR
-7%

For the last 8 years the compound annual growth rate for Biosyent Inc's operating income is 5%. The projected CAGR for the next 4 years is -7%.

What is Biosyent Inc's Net Income forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Biosyent Inc's net income is 7%. The projected CAGR for the next 3 years is 5%.

Back to Top